- Tumors1000+
- Pathologic Processes992
- Nervous System Diseases875
- Cancer751
- Pathology740
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes992
- Nervous System Diseases875
- Cancer751
- Pathology740
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PD-L1 negative
- EGFR positive
- EGFR negative
- PR positive
- ALK negative
- KRAS positive
- ER negative
- PR negative
- BRAF positive
- CD20 positive
- ALK positive
- BRAF negative
- BRCA1 positive
- HLA positive
- ROS1 negative
- p16 positive
- MET positive
- BRCA2 positive
- HLA-A positive
- MYC positive
- HR positive
- IDH positive
- PIK3CA positive
- RET positive
- ROS1 positive
- TP53 positive
- p16 negative
- BCL2 positive
- CD19 positive
- IDH negative
- MET negative
- BCL6 positive
- MSS positive
- ANA positive
- BCR-ABL1 positive
- NRAS positive
- PALB2 positive
- RET negative
- TP53 negative
- dMMR positive
- BRCA1 negative
- CD5 positive
- CFTR positive
- Ex19del positive
- HBsAg positive
- HLA negative
- HLA-A negative
- HPV negative
- KRAS negative
- L858R positive
- NTRK positive
- BRCA2 negative
- CCND1 positive
- COL7A1 positive
- FGFR2 positive
- MMR negative
- MSI-H positive
- NTRK negative
- PTEN positive
- RB1 positive
- TTR positive
- anti-dsDNA positive
- ctDNA positive
- ABCA4 positive
- BRCA positive
- CLDN18.2 positive
- FLT3 positive
- HPV positive
- MDM2 positive
- MGMT negative
- MMR positive
- NF1 positive
- RAS positive
- RB1 negative
- T790M positive
- TROP2 negative
- TROP2 positive
- pMMR positive
- APOL1 positive
- APP positive
- C5 positive
- CD23 positive
- DLL3 positive
- EBV positive
- FGFR3 positive
- FLT3 negative
- FMR1 positive
- GPC3 positive
- HRAS positive
- MGMT positive
- MSI-H negative
- NF2 positive
- NRAS negative
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- PiZZ positive
- RAS negative
- RF positive
- RHO positive
- dMMR negative
- p53 positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AGXT positive
- AKT negative
- ALPL positive
- ARID1A positive
- ATM positive
- Aβ1-42 positive
- CD19 negative
- CD20 negative
- CD30 positive
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- DMD positive
- EBV DNA positive
- ER or PR positive
- ER/PR positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GLA positive
- GRN positive
- HBB positive
- HBV DNA negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HR negative
- HRD positive
- HTT positive
- HbE positive
- HbSS positive
- IGHV negative
- IgHV positive
- JAK2 positive
- KIT positive
- Ki67 positive
- L861Q positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSI negative
- MSS negative
- MTAP positive
- MYC negative
- NPM1 positive
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PTEN negative
- Ph positive
- RAF positive
- S768I positive
- SMN1 positive
- SPINK5 positive
- TTR negative
- UGT1A1 positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- del(17p) negative
- dsDNA positive
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- 11q del negative
- 11q del positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p del positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5798 trials
1
2
3
…50